Replacement for Antibiotic Growth Promoters (AGPs): In response to concerns about antibiotic resistance, MOS is utilized as an alternative to Antibiotic Growth Promoters (AGPs) in animal feed. It ...
Liraglutide is under clinical development by Novo Nordisk and currently in Phase III for Obesity. According to GlobalData, Phase III drugs for Obesity have a 44% phase transition success rate (PTSR) ...
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...
Researchers have developed a groundbreaking way to engineer yeast (Saccharomyces cerevisiae) to create microbial communities that can perform complex tasks and self-regulate their composition in ...
Researchers from the Yong Loo Lin School of Medicine (NUS Medicine) have developed a novel way to engineer yeast (Saccharomyces cerevisiae) to create microbial communities that can perform complex ...